Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
no clear plateau) Zepbound: ~20% to 22.5% (long-term studies) Glycemic Control (T2D): Retatrutide: HbA1c reduction up to ~2.0% (Phase III) Zepbound: Strong, well-established HbA1c reductions (~2.0% to 2.4%) across Phase III trials Durability of Effect: Retatrutide: Sustained weight loss with continued decline over time Zepbound: Durable, but tends to plateau earlier Safety & Tolerability: Retatrutide: Higher rates of GI side effects
doi: 10.2337/dc10-1333 12
Feel more confident as they work toward their health goals
Campbell JE, Ussher JR, Mulvihill EE, et al
US$ 29.05
US$ 25.12
US$ 28.63
US$ 27.05
US$ 27.19
